Aytu Biopharma (AYTU) Cost of Revenue (2014 - 2026)

Aytu Biopharma (AYTU) has 13 years of Cost of Revenue data on file, last reported at $4.8 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $4.8 million, down 14.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.9 million (down 20.29% YoY), and the FY2025 annual result was $20.9 million, down 5.33% from the prior year.
• Cost of Revenue slipped to $4.8 million in Q1 2026 per AYTU's latest filing, from $6.0 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $12.2 million in Q2 2023 and troughed at $3.7 million in Q1 2024.
• A 5-year average of $7.3 million and a median of $6.0 million in 2025 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue jumped 65.26% in 2022, then slumped 63.32% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $10.6 million in 2022, then slumped by 50.59% to $5.2 million in 2023, then rose by 4.16% to $5.4 million in 2024, then increased by 10.36% to $6.0 million in 2025, then slipped by 19.77% to $4.8 million in 2026.
• Business Quant data shows AYTU's Cost of Revenue at $4.8 million in Q1 2026, $6.0 million in Q4 2025, and $5.3 million in Q3 2025.